**SELUTION SLR™** drug-eluting balloon (DEB) demonstrates safety and efficacy in First-in-Human coronary study\(^4\) and is designed to deliver similar performance as drug-eluting stents (DES)\(^5\).

- **Primary endpoint - 100% Freedom from device and procedure-related mortality through 30 days.**
- **Low overall MACE rate of 2% at 12 months.**

### Case examples from First-in-Human Coronary Study

#### Hybrid Approach (DES & DEB)

- **Pre-intervention**
- **At 6 months follow-up**

#### Bifurcations

#### Small Vessels

#### In-Stent Restenosis

---

**Ordering Information**

**SELUTION SLR™ Sirolimus Eluting PTCA Balloon Catheter**

<table>
<thead>
<tr>
<th>Balloon Diameter (mm)</th>
<th>Action Length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.50</td>
<td>SC14-150010</td>
</tr>
<tr>
<td>2.00</td>
<td>SC14-200010</td>
</tr>
<tr>
<td>2.50</td>
<td>SC14-250010</td>
</tr>
<tr>
<td>2.75</td>
<td>SC14-275010</td>
</tr>
<tr>
<td>3.00</td>
<td>SC14-300010</td>
</tr>
<tr>
<td>3.50</td>
<td>SC14-350010</td>
</tr>
<tr>
<td>3.75</td>
<td>SC14-375010</td>
</tr>
<tr>
<td>4.00</td>
<td>SC14-400010</td>
</tr>
<tr>
<td>4.50</td>
<td>SC14-450010</td>
</tr>
<tr>
<td>5.00</td>
<td>SC14-500010</td>
</tr>
</tbody>
</table>

---

**Technical Specification**

- **Sirolimus Drug Dose:** 1.0μg/mm²
- **Drug Carrier Cell Adherent Technology (CAT™):** Amphipathic Lipid Carrier
- **Catheter Design:** Rapid Exchange (RX)
- **Shaft Diameter:** 1.9 Fr (0.63mm)
- **Catheter Usable Length:** 140cm
- **Guidewire Compatibility:** 0.014"
- **Minimum Guide Catheter Compatibility (Fr):**
  - ≥ 5Fr: 1.50 – 3.75mm balloon diameter
  - ≥ 6Fr: 4.00 – 5.00mm balloon diameter

---

**SELUTION SLR and CAT are trademarks of MedAlliance CardioVascular SA.**

© 2020 MedAlliance CardioVascular SA.

Indication, contraindications and warnings can be found in the instructions for use supplied with each device.

SELUTION SLR Sirolimus Eluting PTCA Balloon Catheter - CE Mark Approved. Not available for sale in United States.

Legal Manufacturer: MedAlliance Cardiovascular SA, Rue de Rive 5, 1260 Nyon, Switzerland

T: + 41 22 363 78 90
E: info@medalliance.com
W: www.medalliance.com

SAM-0004 Rev.A

---

**The New Paradigm for Coronary Interventions**
The new Paradigm for Coronary Interventions.

Don’t compromise on your treatment standard... SOLUTION SLR™ is the latest generation of Drug-Eluting Balloon technology.

• Offering you a greater choice of options for your coronary interventions.

• Designed to deliver the same safety and performance as the best-in-class DES technology with the added benefit of “leaving nothing behind”.

Breakthrough Technology to Deliver Sustained Limus Release for up to 90 days

Cell Adherent Technology (CAT™) is a proprietary amphipathic lipid technology which binds the MicroReservoirs to the balloon surface, protecting them during balloon insertion and inflation;

• Enhancing drug retention and bioavailability, allowing for a lower drug dose concentration on the balloon surface (1μg/mm²);

• Optimizing transfer of MicroReservoirs to the tissue and maximizing the cellular uptake of sirolimus.

MicroReservoirs form millions of precision-engineered drug delivery systems, combining sirolimus with a biodegradable polymer, achieving consistent and predictable drug release;

• Optimizing MicroReservoir size to achieve a pharmaco-kinetic release profile comparable to the latest generation DES technology.

Latest Generation of PTCA Balloon

• Offering a broader portfolio for coronary indications with balloon diameters ranging from 1.50mm to 5.00mm and lengths from 10mm to 40mm.